Biotech Veteran Urs Spitz to Steer Ribbon Bio's DNA Revolution

VIENNA, AU – April 08, 2026 – In a strategic move signaling a new phase of ambitious growth, cell-free DNA assembly pioneer Ribbon Bio has appointed Dr. Urs Spitz as the new Chair of its Board of Directors. The appointment brings a nearly three-decade track record of scaling life sciences companies to the Vienna-based firm as it prepares to commercialize its revolutionary DNA synthesis platform.

Dr. Spitz is a recognized figure in the life sciences industry, best known for his transformative leadership at Biosynth. His appointment is widely seen as a major validation of Ribbon Bio's technology and a clear indicator of the company's intent to move from a research-focused startup to a dominant commercial entity in the rapidly expanding synthetic biology market.

"We're thrilled to welcome Urs as our Chairman at such a defining moment for Ribbon," said Ribbon CEO, Jodi Barrientos, in a statement. "His experience and strategic perspective will be invaluable as we work to make DNA more accessible and transform the cell-free DNA market."

An Architect of Exponential Growth

Dr. Spitz's reputation as a builder of life sciences powerhouses is well-earned. During his tenure as CEO and co-owner of Biosynth, which began in 2005, he orchestrated the company's evolution from a modest regional business into a global supplier of critical raw materials for the pharmaceutical and diagnostics industries. Under his leadership, Biosynth saw its workforce swell from 70 employees in 2014 to over 600 by late 2023, with revenues skyrocketing from $30 million to $150 million in the same period.

This explosive growth was fueled by a shrewd combination of organic expansion and a targeted acquisition strategy. Dr. Spitz led a series of key purchases that significantly broadened Biosynth's capabilities, particularly in the high-value peptide synthesis space. Acquisitions included US-based Vivitide in March 2022, Dutch peptide specialist Pepscan in June 2022, and UK-based Cambridge Research Biochemicals in May 2023, among others. Each move solidified Biosynth's position as an indispensable partner to global life science firms.

The culmination of this strategy came in 2022 with the successful sale of a majority stake to KKR, a leading global investment firm. The acquisition, made through KKR's $4 billion Health Care Strategic Growth Fund II, was a testament to the value Dr. Spitz and his team had built. His ability to navigate a company through such rapid scaling and secure a major private equity exit is precisely the experience Ribbon Bio sought to bring into its boardroom.

Beyond Bacteria: The Cell-Free DNA Frontier

Ribbon Bio is tackling one of the most significant bottlenecks in modern biotechnology: the synthesis of DNA. For decades, researchers have relied on methods that are either slow and cumbersome or limited in the complexity of the DNA they can produce. Traditional plasmid-based approaches, which use bacteria like E. coli as living factories, are time-consuming and often introduce impurities. Chemical synthesis methods, while effective for short DNA strands (oligos), struggle with accuracy and yield as the length of the desired molecule increases.

Ribbon Bio's platform circumvents these issues by taking the biological machinery out of the cell. Its proprietary cell-free system uses a sophisticated combination of enzymes and advanced software algorithms to assemble long, complex DNA molecules from smaller, intelligently designed oligo pools. This approach promises to deliver DNA that is not only purer but can also feature unprecedented length and structural complexity—qualities that are crucial for next-generation research and therapeutic development.

"I am fascinated by Ribbon Bio's ambition to provide reliable and quick access to complex, cell-free DNA to accelerate the next wave of breakthroughs in biotechnology," Dr. Spitz stated. He described the company's platform as an "'impossible' platform that combines enzymes and software to enable simple and robust, hardware-agnostic workflows."

This technology places Ribbon Bio at the forefront of a major shift towards enzymatic and cell-free DNA synthesis. While competitors like Twist Bioscience have mastered high-throughput synthesis of shorter genes and DNA Script offers benchtop enzymatic synthesis, Ribbon's focus on assembling exceptionally large and complex constructs could carve out a critical, high-value niche in the market.

A Defining Moment in a Burgeoning Market

The timing of Dr. Spitz's appointment could not be more opportune. The synthetic biology market is experiencing explosive growth, with some projections estimating the synthetic DNA market alone could surge from approximately $2.6 billion in 2023 to nearly $19 billion by 2033. This growth is driven by a voracious demand from pharmaceutical and biotech companies for custom DNA to fuel R&D in gene therapy, vaccine development, diagnostics, and advanced biologics.

Crucially, as scientific ambition grows, so does the need for the very kind of DNA that Ribbon Bio aims to produce: long, high-fidelity, and structurally complex. The company's technology is poised to directly address the limitations that currently constrain innovation. By providing researchers with the exact genetic material they design, free from biological constraints and delivered with speed and reliability, the firm aims to fundamentally change the pace of discovery.

Bringing Dr. Spitz on board is a clear signal to investors and the market that Ribbon Bio is ready to commercialize this potential. His experience at Biosynth—scaling operations, integrating acquisitions, and navigating the path to a successful, high-value exit—provides a strategic roadmap for Ribbon Bio's own journey. His leadership will be instrumental in guiding the company as it builds its manufacturing capabilities, forges key partnerships, and establishes itself as a foundational tool provider for the entire biotechnology ecosystem.

Unlocking the Future of Health and Sustainability

The ultimate vision for Ribbon Bio, as articulated by the company and its new Chairman, extends far beyond the laboratory. The mission to "democratize the use of synthetic DNA" has profound implications for solving some of the world's most pressing challenges. In medicine, faster and more reliable access to complex DNA could dramatically accelerate the development of personalized cancer therapies, novel vaccines for emerging infectious diseases, and cures for rare genetic disorders.

Beyond human health, the technology holds promise for planetary health. In agriculture, it can facilitate the engineering of crops with greater resistance to drought and pests, improving food security in a changing climate. In industrial biotechnology, it can enable the design of microorganisms that produce sustainable biofuels, biodegradable plastics, and other valuable chemicals from renewable resources, reducing reliance on fossil fuels.

By removing a fundamental bottleneck in the design-build-test cycle of synthetic biology, Ribbon Bio's platform could empower a new generation of innovators across countless fields. With the strategic guidance of Dr. Urs Spitz now at the helm, the company is strongly positioned to not just transform the market for DNA synthesis, but to supply the very building blocks of the next scientific and industrial revolution.